Receptor tyrosine kinases: Role in cancer progression

Current Oncology

Volumn 13, Issue 5, 2006, Pages 191-193

  Sangwan, V ^a   Park, Morag ^a,b  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Cancer; Receptor tyrosine kinase

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ERLOTINIB; GEFITINIB; PROTEIN TYROSINE KINASE; TRASTUZUMAB;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER GROWTH; CELL PROLIFERATION; HEAD AND NECK CANCER; HUMAN; MEDICAL PRACTICE; MEDICAL RESEARCH;

EID: 33750855574     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Pawson T, Scott JD. Protein phosphorylation in signalling- 50 years and counting. Trends Biochem Sci 2005;30:286-90.
2. Wiley HS, Burke PM. Regulation of receptor tyrosine kinase signaling by endocytic trafficking. Traffic 2001;2:12-18.
3. Peschard P, Park M. Escape from cbl-mediated downregulation: a recurrent theme for oncogenic deregulation of receptor tyrosine kinases. Cancer Cell 2003;3:519-23.
4. Bache KG, Slagsvold T, Stenmark H. Defective downregulation of receptor tyrosine kinases in cancer. Embo J 2004;23:2707-12.
5. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001;411:355-65.
6. Jones SM, Kazlauskas A. Growth-factor-dependent mitogenesis requires two distinct phases of signalling. Nat Cell Biol 2001;3:165-72.
7. Maulik G, Kijima T, Salgia R. Role of receptor tyrosine kinases in lung cancer. Methods Mol Med 2003;74:113-25.
8. Folkman J. Incipient angiogenesis. J Natl Cancer Inst 2000;92:94-5.
9. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006;124:263-6.
10. Baselga J. Targeting tyrosine kinases in cancer: the second wave. Science 2006;312:1175-8.
11. Romond EH, Perez EA, Bryant J. et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
12. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.
13. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
14. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-9.